Given that cDC2 is involved in CD4+ T cell differentiation and activation, CD300a on cDC2, rather than cDC1, may regulate Treg cells activation by inhibiting the TLR3–IFN-β pathway in tumor microenvironment. Here, CD4 is linked to neoplasm.